Jan Berger, MD, MJ, president & CEO, Health Intelligence Partners, and editor-in-chief of The American Journal of Pharmacy Benefits, says that historically medication adherence, when it pertained to PBMs, was really just about selling pills-it was an isolated, siloed issue.
Jan Berger, MD, MJ, president & CEO, Health Intelligence Partners, and editor-in-chief of The American Journal of Pharmacy Benefits, says that historically medication adherence, when it pertained to PBMs, was really just about selling pills—it was an isolated, siloed issue. However, pharmacy benefit managers (PBMs) began to recognize that clients were looking at adherence in a bigger, broader sense as they realized how adherence affected their lives, out-of-pocket costs, and workability.
Dr Berger also says that one of the newer areas PBMs are focusing on are medication adherence outcomes.
“Are people take their medications, and if they’re not, what are those barriers that need to be overcome in order to take it?" asks Dr Berger. "So like the rest of healthcare, we are going from a process-oriented world, to an outcomes-oriented world.”
ACA Network Regulatory Filings Are Inaccurate, Poorly Match Provider Directories
September 16th 2025A secret shopper survey (N = 8306) in Pennsylvania’s Affordable Care Act (ACA) Marketplace found inconsistencies between carrier regulatory filings and provider directories, frequent inaccuracies in regulatory filings, and challenges in securing timely appointments.
Read More
Impact of Amivantamab-Lazertinib on EGFR, MET Resistance Alterations in NSCLC: Danny Nguyen, MD
September 15th 2025The combination of amivantamab and lazertinib in first-line non–small cell lung cancer (NSCLC) significantly reduces resistance mechanisms with implications for second-line treatment, said Danny Nguyen, MD, of City of Hope.
Read More